门 昌红 科 技 证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-----------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------- ...

证券代码: 300151 证券简称：昌红科技 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 投资者关系活动记录表 编号：2022-007 | --- | --- | --- | |---------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

深圳市昌红科技股份有限公司 2022 年第三季度报告 证券代码：300151 证券简称：昌红科技 公告编号：2022-080 债券简称: 昌红转债 债券代码: 123109 深圳市昌红科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 深圳市昌红科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|--- ...

深圳市昌红科技股份有限公司 2022 年半年度报告全文 深圳市昌红科技股份有限公司 Shen Zhen Changhong Technology Co.,Ltd. （深圳市坪山区碧岭街道沙湖社区锦龙大道 3 号昌红科技公司 1 层至 3 层） 2022 年半年度报告 【2022 年 8 月】 1 深圳市昌红科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李焕昌、主管会计工作负责人周国铨及会计机构负责人(会计 主管人员)朱金凤声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第三节"管理层讨论与分析之十、公司面临的风险和应对 措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投资 者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 深圳市昌红科技股份有限公司 2022 年半年度报告全文 目录 | --- | |------- ...

深圳市昌红科技股份有限公司 2022 年第一季度报告全文 □ 是 √ 否 1 证券代码：300151 证券简称：昌红科技 公告编号：2022-036 债券代码：123109 证券简称：昌红转债 深圳市昌红科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3、第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 本报告期 上年同期 本报告期比上年同期增减 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|--------- ...

深圳市昌红科技股份有限公司 2021 年年度报告全文 深圳市昌红科技股份有限公司 Shen Zhen Changhong Technology Co.,Ltd. （深圳市坪山区碧岭街道沙湖社区锦龙大道 3 号昌红科技公司 1 层至 3 层） 2021 年年度报告 2022 年 04 月 1 深圳市昌红科技股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人李焕昌、主管会计工作负责人周国铨及会计机构负责人(会计主 管人员)朱金凤声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司经营中可能存在的风险及应对措施，详见本报告"第三节 管理层讨论 与分析"之"十一 公司未来发展的展望"中"公司可能面对的风险和应对措施"部 分。公司 2022 年度的经营计划不构成公司对投资者的业绩承诺，投资者应对此 保持足够的风险意识，应理解经营计划与业绩承诺之间的差异。敬请广大投资 者关注，并注意投资风险。 ...

Financial Performance - The company reported a total revenue of 496,597,221.00 RMB for the year 2021, with a cash dividend of 1.80 RMB per 10 shares distributed to shareholders[7]. - The company's operating revenue for 2021 was CNY 1,127,382,018.70, representing a 0.84% increase from CNY 1,118,018,432.98 in 2020[29]. - The net profit attributable to shareholders for 2021 was CNY 111,841,084.78, a decrease of 33.77% compared to CNY 168,868,134.87 in 2020[29]. - The net profit after deducting non-recurring gains and losses was CNY 87,634,980.06, down 42.49% from CNY 152,373,837.81 in 2020[29]. - The net cash flow from operating activities was CNY 97,106,056.55, a decline of 58.26% from CNY 232,620,881.12 in 2020[29]. - The total assets at the end of 2021 amounted to CNY 1,906,571,742.00, an increase of 43.34% from CNY 1,330,099,588.54 at the end of 2020[29]. - The net assets attributable to shareholders at the end of 2021 were CNY 1,159,847,519.83, reflecting an 11.24% increase from CNY 1,042,680,701.52 at the end of 2020[29]. - The basic earnings per share for 2021 was CNY 0.25, down 34.21% from CNY 0.38 in 2020[29]. - The total profit for 2021 was 130.66 million yuan, a decrease of 39.28% compared to the previous year[78]. - The gross margin improved to 35% in 2021, up from 30% in 2020, reflecting better cost management and pricing strategies[198]. Market Expansion and Strategy - The company plans to expand its market presence and enhance product offerings, focusing on new technologies and product development in the medical device sector[7]. - The company aims to enhance its market position by focusing on high-quality domestic medical device products, encouraged by recent government policies[50]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[198]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's production capacity by 40%[198]. - The company plans to invest 100 million yuan in research and development over the next two years to innovate new technologies[198]. Research and Development - The company has a focus on research and development, particularly in the field of in vitro diagnostic products (IVD) and precision medical devices[21]. - The company has completed the development of a nucleic acid extraction kit (machine version) and achieved mass production, enhancing efficiency in pandemic prevention efforts[106]. - The nucleic acid extraction kit (handheld version) has also been completed and is in mass production, providing flexible sample extraction capabilities[106]. - The company is in the trial production phase for a fluorescence quantitative PCR dedicated 384 experimental consumable, aimed at automating and enhancing detection efficiency[106]. - The company is committed to continuous R&D in precision mold design, injection molding technology, and automation technology to maintain industry leadership[162]. - In 2021, the company's R&D investment amounted to ¥47,467,967.71, representing 4.21% of operating revenue, an increase from 3.57% in 2020[113]. - The number of R&D personnel increased by 22.90% from 214 in 2020 to 263 in 2021, with R&D personnel now accounting for 11.67% of the total workforce[112]. Operational Efficiency - The company aims to reduce operational costs by 10% through efficiency improvements and automation initiatives[198]. - The company aims to leverage advanced manufacturing technologies, including CAD and CAM, to enhance production efficiency and product quality[21]. - The company has implemented various information systems to enhance management efficiency and reduce costs[86]. - The company emphasizes continuous technological innovation and market expansion, which has established a strong reputation in the industry[71]. Risk Management - The company emphasizes the importance of risk management and has outlined potential risks and corresponding mitigation strategies in its future outlook[7]. - The company recognizes the risk of management challenges due to rapid business expansion and is working to improve its management systems[165]. - The company is closely monitoring exchange rate fluctuations, as its foreign sales are primarily denominated in USD and EUR[164]. Corporate Governance - The company held 5 shareholder meetings in 2021, ensuring equal rights for all shareholders and protecting minority investors' interests[172]. - The company maintained independence from its controlling shareholder in personnel, assets, finance, organization, and business, with no guarantees provided to the controlling shareholder or its affiliates[173]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[174]. - The company established a performance evaluation and incentive mechanism to motivate employees, with a transparent performance assessment standard[176]. - The company strictly adhered to information disclosure regulations, ensuring timely and fair information dissemination to all shareholders[178]. - The company has a robust internal control management system, maintaining effective financial reporting controls without significant deficiencies[180]. Subsidiaries and Investments - The company has established several subsidiaries, including Shenzhen Baiming Sheng Medical Equipment Co., Ltd., to strengthen its operational capabilities and market reach[16]. - The company has established a new subsidiary, Zhejiang Baiming Sheng Medical Technology Co., Ltd., which is currently in the infrastructure construction phase[150]. - The subsidiary Shenzhen Baiming Sheng Medical Device Co., Ltd. reported a net profit of CNY 41,832,633.22, contributing significantly to the company's overall performance[150]. - The total amount raised from the issuance of convertible bonds was RMB 44,773.77 million, with RMB 18,609.63 million utilized by the end of the reporting period[128]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[198]. - Future guidance indicates an expected EBITDA margin of 20% for the upcoming fiscal year, driven by increased sales and operational efficiencies[198].

深圳市昌红科技股份有限公司 2021 年第三季度报告 □ 是 √ 否 1 证券代码: 300151 证券简称：昌红科技 公告编号：2021-100 债券代码: 123109 债券简称: 昌红转债 深圳市昌红科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------------ ...

深圳市昌红科技股份有限公司 2021 年半年度报告全文 深圳市昌红科技股份有限公司 Shen Zhen Changhong Technology Co.,Ltd. （深圳市坪山区碧岭街道沙湖社区锦龙大道 3 号昌红科技公司 1 层至 3 层） 2021 年半年度报告 2021 年 08 月 1 深圳市昌红科技股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人李焕昌、主管会计工作负责人周国铨及会计机构负责人(会计主 管人员)杨兵声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第三节"管理层讨论与分析之十、公司面临的风险和应对措 施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投资者关注 相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 深圳市昌红科技股份有限公司 2021 年半年度报告全文 目录 | --- | |--------- ...